Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-08
2011-03-08
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C424S009341
Reexamination Certificate
active
07902144
ABSTRACT:
The invention relates to transport molecule binding ligand compounds which comprise a therapeutically and/or diagnostically active substance and a carrier molecule-affine substance with a high association constant to the carrier molecule. The invention also relates to medicaments containing these ligand compounds and to diagnostic kits.
REFERENCES:
patent: 4043997 (1977-08-01), Schroeder
patent: 5157044 (1992-10-01), Schoenwald et al.
patent: 5612474 (1997-03-01), Patel
patent: 5919815 (1999-07-01), Shashoua et al.
patent: 6267964 (2001-07-01), Nygren et al.
patent: 6310039 (2001-10-01), Kratz
patent: 0 624 377 (1994-11-01), None
patent: WO 91/05806 (1991-05-01), None
patent: WO 96/39183 (1996-12-01), None
patent: WO 98/08859 (1998-03-01), None
patent: WO 00/02050 (2000-01-01), None
Trouet et al. Proc. Natl. Acad. Sci. vol. 79, pp. 626-629 (1982).
Kratz et al. Biol. Pharm. Bull. 21(1): 56-61 (1998).
Kratz, F. WO 98/10794.
Penichet, M. et al. Journal of Immunology 163: 4421-4426 (1999).
Minks, C. et al. Biochemistry 38: 10649-10659 (1999).
Andresen, T. et al. Progress in Lipid Research 44: 68-97 (2005).
Majumdar, S. et al. Advanced Drug Delivery Reviews 56: 1437-1452 (2004).
Kratz, F. and Beyer, U. Drug Delivery 5: 281-299 (1998).
Hudson, A. et al. International Journal of Pharmaceutics 182: 49-58 (1999).
Abcam product datasheet for Transferrin Receptor antibody, ab25543 (Clone RVS10).
Makrides et al., “Extended in vivo half-life of Human Soluble Complement Receptor Type 1 fused to a Serum Albumin-Binding Receptor”, The Journal of Pharmacology and Experimental Therapeutics 277(1): 534-542 (1996).
Nagy et al., “High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin”, Proc. Natl. Acad. Sci. USA 93: 2464-2469 (1996).
Desai Anand U
KTB Tumorforschungsgesellschaft mbH
Morales Carl A.
Ropes & Gray LLP
Ruskin Barbara A.
LandOfFree
Therapeutic and diagnostic ligand systems comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic ligand systems comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic ligand systems comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690672